DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

Phase 3

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 58

Registration Number: NCT00144209

Locations: 🇨🇭
Boehringer Ingelheim Investigational Site, Zurzach, Switzerland

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Phase 2

Terminated

Conditions: HIV Infections

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 562

Registration Number: NCT00144105

Locations: 🇬🇧
Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom
🇦🇷
Hospital Posadas, Haedo, Argentina
🇧🇷
Universidade Federal do Rio de Janeiro, Rio de Janeiro - RJ, Brazil

and more 59 locations

Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue

Phase 3

Completed

Conditions: Mental Competency
Mental Fatigue

First Posted Date: 2005-09-05

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 412

Registration Number: NCT00144235

Locations: 🇬🇧
Boehringer Ingelheim Investigational Site, Aldershot, United Kingdom

Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis

Phase 3

Completed

Conditions: Pharyngitis

First Posted Date: 2005-09-05

Last Posted Date: 2013-10-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 220

Registration Number: NCT00144274

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Sandton, South Africa

Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

Phase 4

Completed

Conditions: Acquired Immunodeficiency Syndrome

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT00144157

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Soweto, South Africa

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: Mirapex
Drug: Requip

First Posted Date: 2005-09-05

Last Posted Date: 2014-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 246

Registration Number: NCT00144300

Locations: 🇺🇸
248.538.00010 Boehringer Ingelheim Investigational Site, New York, New York, United States
🇺🇸
248.538.00013 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸
248.538.00006 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 18 locations

An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

Phase 4

Completed

Conditions: HIV Infections
Metabolism, Lipids

First Posted Date: 2005-09-05

Last Posted Date: 2025-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT00144261

Locations: 🇳🇱
1100.1426.02 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇳🇱
1100.1426.01 Academic Medical Centre, Amsterdam, Netherlands
🇬🇧
1100.1426.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom

A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 250

Registration Number: NCT00144326

Locations: 🇨🇦
1796 Summer Street, Halifax, Nova Scotia, Canada
🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
🇨🇦
Montreal Chest Institute of the Royal Victoria Hospital, Montreal, Quebec, Canada

and more 21 locations

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

Phase 4

Completed

Conditions: HIV Infections
Hepatic Insufficiency

First Posted Date: 2005-09-05

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 51

Registration Number: NCT00144248

Locations: 🇺🇸
Albany Medical College, MC 142, Albany, New York, United States
🇫🇷
Hopital Pitie Salpetriere, Paris, France
🇺🇸
Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States

and more 3 locations

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

Phase 3

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-08-23

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 345

Registration Number: NCT00133198

Locations: 🇺🇸
Metrohealth Medical Center, Cleveland, Ohio, United States
🇺🇸
Mid America NeuroScience Institute, Lenexa, Kansas, United States
🇺🇸
HealthQuest Clinical Trials Research, San Diego, California, United States

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy